Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$2.66 - $10.04 $1.28 Million - $4.82 Million
479,932 Added 2.78%
17,713,600 $47.6 Million
Q4 2022

Feb 14, 2023

BUY
$4.69 - $8.36 $900,480 - $1.61 Million
192,000 Added 1.13%
17,233,668 $85.8 Million
Q1 2022

May 16, 2022

BUY
$8.75 - $14.51 $1.78 Million - $2.95 Million
203,000 Added 1.21%
17,041,668 $196 Million
Q4 2021

Feb 14, 2022

BUY
$8.98 - $20.09 $151 Million - $338 Million
16,838,668 New
16,838,668 $214 Million

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.